Skip to main
CJC-1295 Compound

An ink-and-paper field guide to the GHRH analog CJC-1295 — with-DAC, no-DAC, and the ipamorelin stack, drawn from the literature.

CJC-1295 References: Bring the Study to Your Visit

The Original Papers Show Who Was Tested and What Changed

CJC-1295 is a growth hormone research compound with limited human testing. The study papers give you the original findings to discuss with your doctor.

Teichman 2006 and Ionescu 2006 studied 24 healthy adults between them. The longest follow-up was a 49-day period, which can't establish risks after years of use.

Other papers studied ipamorelin and tesamorelin, separate compounds that also prompt growth hormone release. Halmos 2025 reviewed the gland's response; each entry names its paper and links to the published source.

I'd bring the paper behind the health claim you're hearing to your visit. Your doctor can check who was studied and whether the result concerns your health.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. ↗
  3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
  4. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. ↗
  5. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
  6. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. ↗
  7. Norman C, Miles J, Bowers CY, Veldhuis JD. Differential pulsatile secretagogue control of GH secretion in healthy men. Am J Physiol Regul Integr Comp Physiol. 2013;305(4):R378-86. ↗
  8. Johannsson G, Sverrisdóttir YB, Ellegård L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab. 2002;87(4):1743-9. ↗
  9. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. ↗
  10. Andersen NB, Malmlöf K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-72. ↗
  11. Aagaard NK, Grøfte T, Greisen J, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009;19(5):426-31. ↗
  12. Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025;Online ahead of print. ↗
  13. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. [Same as citation 1 — adverse events reported in same paper.] J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  14. Jetté L, et al. [Same as citation 3 — DAC/no-DAC structural data reported in same paper.] Endocrinology. 2005;146(7):3052-8. ↗
  15. Jetté L, et al. [Same as citation 3 — DPP-IV resistance and sermorelin half-life comparative data reported in same paper.] Endocrinology. 2005;146(7):3052-8. ↗
  16. U.S. Food and Drug Administration Pharmacy Compounding Advisory Committee. Bulk drug substances nominated for 503A inclusion — December 2024 meeting. FDA Docket FDA-2024-N-4777. ↗
  17. Jetté L, et al. [Oral bioavailability inference from MW and SC route documented in same paper.] Endocrinology. 2005;146(7):3052-8. ↗
  18. Ionescu M, Frohman LA. [Same as citation 2 — GH suppression absence and pulsatility preservation.] J Clin Endocrinol Metab. 2006;91(12):4792-7. ↗
  19. Teichman SL, et al. [Same as citation 1 — HPG axis not measured; no testosterone data.] J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  20. Ionescu M, Frohman LA. [MK-677 vs CJC-1295 mechanistic comparison context — GH pulse profile data from same paper.] J Clin Endocrinol Metab. 2006;91(12):4792-7. ↗
  21. Various authors. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. ScienceDirect (in press 2026). ↗